Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha has received investment commitments worth ₹7,043 crore across the pharmaceutical and medical technology sectors, marking a major step in strengthening the state’s position as an emerging healthcare manufacturing hub.

The announcements were made during high-level industry interactions led by the state government, reflecting strong investor confidence in Odisha’s policy framework and industrial infrastructure.

The proposed investments cover pharmaceutical formulations, bulk drugs, medical devices, and allied healthcare manufacturing.

Chief Minister Mohan Charan Majhi said the inflow of investments underscores Odisha’s commitment to building a competitive and innovation-driven industrial ecosystem. “Odisha is focused on creating an enabling environment for pharma and medtech companies through robust infrastructure, transparent governance, and investor-friendly policies.”

Beyond manufacturing scale-up, the investments are expected to drive research, innovation, and technology transfer in the pharma and medtech sectors.

Industries Minister Sampad Chandra Swain highlighted that targeted incentives and sector-specific parks are helping attract long-term investments. “With dedicated industrial clusters and fast-track approvals, Odisha is positioning itself as a preferred destination for pharma and medical device manufacturing.”

He added that the government is working closely with investors to ensure timely project execution and seamless operational support.

Looking ahead, the Odisha government plans to convert these commitments into on-ground projects through continued industry engagement, reinforcing the state’s alignment with national initiatives such as Make in India and Atmanirbhar Bharat, while building a sustainable healthcare manufacturing ecosystem.

Related Posts

AbbVie loses patent plea for Hep C drug

New Delhi: The Indian Patent Office has refused to grant a secondary patent to AbbVie for its blockbuster Hepatitis C drug combination glecaprevir/pibrentasvir, sold globally under the brand name Maviret.…

GSK’s Calpol a well-known trademark: High Court

New Delhi: In a relief to UK-headquartered GlaxoSmithKline Pharmaceuticals (GSK), the Delhi High Court has declared its pain and fever medicine ‘Calpol’ as a well-known trademark that has acquired extensive…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug

GSK’s Calpol a well-known trademark: High Court

GSK’s Calpol a well-known trademark: High Court

3 arrested for allegedly posing as doctors using forged MBBS degrees

3 arrested for allegedly posing as doctors using forged MBBS degrees

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer